Sensitization to anti-PD1 was dependent on and negatively correlated with the proportion of tumor-resident neutrophils, as manipulated by tumor neutrophil-increasing granulocyte colony-stimulating factor treatment or neutrophil-depleting anti-Ly6G treatment (Extended Data Figs. 8a,d–e and 10). The gene discussed is CSF3; the disease is neoplasm.